JT-003

Jeil Pharmaceutical Co., Ltd. · Phase 3 active Small molecule

JT-003 is an investigational therapeutic agent in phase 3 development by Jeil Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.

At a glance

Generic name	JT-003
Sponsor	Jeil Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Without access to detailed clinical trial data or company disclosures, the precise molecular target and mechanism remain unknown. Phase 3 status indicates the drug has demonstrated sufficient efficacy and safety in earlier trials to warrant large-scale clinical evaluation.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results